Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy C Jones

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|January 12, 2011
Identification of the minimal active sequence of an anti-influenza virus peptideJeremy C Jones, Erik W Settles, Curtis R Brandt, et al.
Antiviral Research|December 25, 2022
Influenza antivirals and their role in pandemic preparednessJeremy C Jones, Hui-Ling Yen, Peter Adams, et al.
Antiviral Research|November 3, 2022
Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B virusesPhilippe Noriel Q Pascua, Jeremy C Jones, Richard J Webby, et al.
Journal of Virology|September 29, 2006
Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cellsJeremy C Jones, Elizabeth A Turpin, Hermann Bultmann, et al.
Antiviral Research|July 10, 2024
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitorsKonstantin Andreev, Jeremy C Jones, Patrick Seiler, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B VirusesJeremy C Jones, Bindumadhav M Marathe, Peter Vogel, et al.
Antiviral Research|June 23, 2022
Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavirJeremy C Jones, Samuel W Rovito, Melissa K Penaflor, et al.
Nature Communications|February 19, 2026
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in miceKonstantin Andreev, Jeremy C Jones, Ahmed Kandeil, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2020
Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibitionJeremy C Jones, Philippe N Q Pascua, Walter N Harrington, et al.
Nature Microbiology|March 18, 2025
Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow's milkJeremy C Jones, Konstantin Andreev, Thomas P Fabrizio, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|January 12, 2011
Identification of the minimal active sequence of an anti-influenza virus peptideJeremy C Jones, Erik W Settles, Curtis R Brandt, et al.
Antiviral Research|December 25, 2022
Influenza antivirals and their role in pandemic preparednessJeremy C Jones, Hui-Ling Yen, Peter Adams, et al.
Antiviral Research|November 3, 2022
Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B virusesPhilippe Noriel Q Pascua, Jeremy C Jones, Richard J Webby, et al.
Journal of Virology|September 29, 2006
Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cellsJeremy C Jones, Elizabeth A Turpin, Hermann Bultmann, et al.
Antiviral Research|July 10, 2024
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitorsKonstantin Andreev, Jeremy C Jones, Patrick Seiler, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B VirusesJeremy C Jones, Bindumadhav M Marathe, Peter Vogel, et al.
Antiviral Research|June 23, 2022
Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavirJeremy C Jones, Samuel W Rovito, Melissa K Penaflor, et al.
Nature Communications|February 19, 2026
Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in miceKonstantin Andreev, Jeremy C Jones, Ahmed Kandeil, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2020
Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibitionJeremy C Jones, Philippe N Q Pascua, Walter N Harrington, et al.
Nature Microbiology|March 18, 2025
Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow's milkJeremy C Jones, Konstantin Andreev, Thomas P Fabrizio, et al.
Pageof 8